Theriva Biologics, Inc.
Income Statement
| Line Item | FY2011 | FY2010 |
|---|---|---|
| Revenue | $0 | $2.6M |
| Cost of Revenue | — | — |
| Gross Profit | — | — |
| Gross Margin | — | — |
| Operating Expenses | ||
| Research & Development | $3.3M | $1.6M |
| SG&A Expense | $2.6M | $2.1M |
| Operating Income | $-5.9M | $-1.1M |
| Operating Margin | — | -41.4% |
| Interest Expense | — | — |
| Pretax Income | $-5.9M | $-1.1M |
| Income Tax Expense | $0 | — |
| Net Income | $-8.1M | $-1.7M |
| Net Margin | — | -65.5% |
| EPS (Basic) | $-0.02 | $0.00 |
| EPS (Diluted) | $-0.02 | $0.00 |
| Shares Outstanding (Basic) | 563.3M | 420.1M |
| Shares Outstanding (Diluted) | 563.3M | 420.1M |
| Dividends Per Share | — | — |